Taking aim at HDL-C. Raising levels to reduce cardiovascular risk

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Coronary heart disease (CHD) management has been transformed by statin therapy.
• While statins effectively lower low-density lipoprotein cholesterol (LDL-C), this is not the sole determinant of cardiovascular risk.
• Elevated high-density lipoprotein cholesterol (HDL-C) is recognized for its crucial role in cardioprotection.

Purpose of the Study:

• To examine the evidence supporting high-density lipoprotein cholesterol (HDL-C) as a therapeutic target.
• To underscore the importance of HDL-C in reducing the risk of heart attack and stroke.
• To provide a rationale for incorporating HDL-C modulation into cardiovascular risk reduction strategies.

Main Methods:

• Review of existing scientific literature and clinical trial data.
• Analysis of epidemiological studies on lipid profiles and cardiovascular events.
• Examination of the biological mechanisms underlying HDL-C's cardioprotective effects.

Main Results:

• Evidence demonstrates a strong correlation between increased plasma HDL-C concentrations and reduced cardiovascular risk.
• HDL-C plays a significant role in preventing atherosclerosis and promoting reverse cholesterol transport.
• The cardioprotective effects of HDL-C are independent of, and complementary to, LDL-C lowering.

Conclusions:

• High-density lipoprotein cholesterol (HDL-C) represents a vital therapeutic target for cardiovascular risk reduction.
• Strategies aimed at increasing HDL-C levels hold significant potential for mitigating heart attack and stroke.
• Further research and clinical application focusing on HDL-C modulation are warranted for comprehensive cardiovascular disease management.